Teva debuts generic of Provigil, Avapro and Avalide; Ranbaxy Crestor copy OKed in Canada
Israeli generics giant Teva Pharmaceutical Industries (Nasdaq: TEVA) last Friday launched an authorized generic of Provigil (modafinil), a drug for the treatment of narcolepsy, the patent on which expires in 2014.
Provigil is marketed by Cephalon, now a wholly owned subsidiary of Teva which out bid Valeant with a $6.8 bid to acquire the company last year (The Pharma Letter May 3, 2011). This product will continue to be manufactured under the brand product's new drug application at the same facility where it is currently produced. Shipping of the product has commenced. The brand product had annual sales of around $1.1 billion in the USA, based on IMS sales data quoted by Teva.
Teva also announced today that it has commenced commercial launch of both irbesartan and irbesartan-hydrochlorothiazide tablets, the Company’s generic versions of French drug major Sanofi’s high blood pressure treatments, Avapro and Avalide. The brand products had annual sales of around $464 million and $124 million, respectively, in the USA, based on IMS sales data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze